2-Cyanophenylboronic Acid 1,3-Propanediol Ester CAS 172732-52-4 Perampanel Intermediate Purity >99.0% (HPLC)

2-Cyanophenylboronic Acid 1,3-Propanediol Ester (CAS: 172732-52-4) is used in the synthesis of Perampanel (CAS: 380917-97-5), an AMPA receptor antagonist. Perampanel (licensed in 2012) is a third- generation AED known with the proprietary brand name of Fycompa® (Eisai, Hatfield) in the UK and Banzel® (Eisai, Hatfield) in the USA. In October 2012, the US FDA approved perampanel for the treatment of partial onset seizures in epileptic patients who are at least 12 years old. Perampanel is the first AMPA receptor antagonist to receive FDA approval as an AED. AMPA glutamate receptors are found primarily on postsynaptic neurons in the brain. As a selective, noncompetitive antagonist of AMPA, parampanel prevents ion channel opening and reduces propagation of action potential. Perampanel was approved by European EMA and US FDA in July and October 2012 respectively, it is used for adjuvant treatment of patients with partial seizures over 12 years old with or without secondary systemic seizures. On June 22, 2015, Eisai announced that the US FDA has approved the expansion of the indication of Pirenparanide hydrate (Fycompa) as an adjuvant treatment for primary comprehensive tonic-clonic seizures in patients with epilepsy aged 12 and above.